About PreEmptive Meds
More than 50 million people have either fasting blood sugar or cholesterol which is higher than normal, but not severe enough to be considered diabetes or serious heart disease. This is referred to as "Pre-Disease" and is the primary focus of PMI's first two products: PreCrea which lowers blood sugar and PreLipid which reduces overall cholesterol and low-density lipoprotein (LDL; bad cholesterol) and triglyceride levels and improves the level of high-density lipoprotein (HDL; good cholesterol). Doctors are reluctant to prescribe strong drugs for pre-disease and most acknowledge that OTC products have value.PMI's products represent viable options for preempting disease or assisting in medical treatment and are supported by meaningful clinical data. PMI is recruiting a highly regarded sales team. In April 2008, PMI received one of Capital Midwest Fund's first investments.
Missing: PreEmptive Meds's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: PreEmptive Meds's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing PreEmptive Meds
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
PreEmptive Meds is included in 2 Expert Collections, including Beauty & Personal Care.
Beauty & Personal Care
These startups aim to provide health treatments, diagnosis tools, and products that do not require a prescription or connection with a health professional to enhance personal wellbeing. This includes supplements, women's health maintenance, OTC medicines, and more.
PreEmptive Meds Frequently Asked Questions (FAQ)
When was PreEmptive Meds founded?
PreEmptive Meds was founded in 2006.
Where is PreEmptive Meds's headquarters?
PreEmptive Meds's headquarters is located at 3 Saxton Lane, Lebanon.
What is PreEmptive Meds's latest funding round?
PreEmptive Meds's latest funding round is Series C.
How much did PreEmptive Meds raise?
PreEmptive Meds raised a total of $500K.
Who are the investors of PreEmptive Meds?
Investors of PreEmptive Meds include Capital Midwest Fund.
Who are PreEmptive Meds's competitors?
Competitors of PreEmptive Meds include Ikaria, Sorbent Therapeutics, Fate Therapeutics, OptiMedica, Q Therapeutics and 11 more.
Compare PreEmptive Meds to Competitors
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
Quark Pharmaceuticals is a development-stage pharmaceutical company discovering and developing RNA interference (RNAi)-based therapeutics.
OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.
Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.
Alvine Pharmaceuticals is a clinical-stage, specialty biopharmaceutical company focused on the development of biologics targeting autoimmune and inflammatory diseases, including celiac disease. Alvine is focusing clinical development efforts on ALV003, an investigational drug in phase 2 trials that could potentially be the first approved therapeutic treatment for patients with celiac disease. ALV003 is an orally administered mixture of two recombinant gluten-specific proteases, a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP). ALV003 targets gluten and degrades it into small fragments, which, in vitro, diminishes its immunogenicity. ALV003 is being developed as a potential treatment for celiac disease patients in conjunction with a gluten-free diet and is currently in phase 2 clinical development.
With the emphasis on "cure", this company is dedicated to the development of progenitor cell-based regenerative therapeutics. It seeks to provide new treatment options to patients suffering from cardiac or peripheral vascular diseases.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.